Evome Medical Technologies Inc. (EVMT) fair value: what the stock is really worth
As of Jul 22, 2026: fair value of Evome Medical Technologies Inc. C$0.01, price C$0.01, upside +25.0%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Evome Medical Technologies Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 5, 2026.
How to read this chart
60‑month range C$0.0050 – C$1.41 · fair‑value band C$0.0058 – C$0.0073 · the C$0.0050 price screens below the C$0.0063 fair value. Dashed = 300-day average. As of Jul 5, 2026.
Follow Evome Medical Technologies in your weekly email
Every Wednesday you see whether Evome Medical Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evome Medical Technologies Inc. designs, develops, produces, and sells medical devices in the United States. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. The company is based in Shirley, New York.
Stock analysis
Evome Medical Technologies Inc. (EVMT) currently trades at C$0.0050, while our model-based Fair Value estimate is C$0.0063, implying the stock looks roughly 20.0% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the evidence level at low.
Scenario range: C$0.0058 (bear) to C$0.0073 (bull), the price of C$0.0050 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Evome Medical Technologies Inc. reported revenue of C$62.6M in FY2023 versus C$352K in FY2019, a compound +265.2%/yr. Reported net income was −C$15.6M in FY2023.
Key figures
Market cap C$399K (≈ $280K) · EPS (TTM) C$−0.2900 · Net margin −24.9% · Return on equity −295% · Return on assets (EBIT) −17.6% · Operating margin −4.6% · Revenue (TTM) C$48.3M · Revenue growth (YoY) −49.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 25%, EVMT screens cheaper than that median.
Fair Value models
Bear C$0.0058Fair Value C$0.0063Bull C$0.0073
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−372.3% (2019) → −9.8% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
Compare Evome Medical Technologies Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+25.0% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−6.7% · Below median
Net margin (TTM)−48.7% · Bottom 25%
Operating margin (TTM)−4.6% · Below median
Growth and dividend
Revenue growth−49.0% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Evome Medical Technologies Inc. Fair Value". https://www.fairvalue-calculator.com/stock/EVMT
Frequently asked questions
Is Evome Medical Technologies Inc. (EVMT) overvalued or undervalued?
As of Jul 5, 2026, our model estimates a fair value of C$0.0063 versus the last price from Jul 22, 2026 of C$0.0050, about +25% upside (undervalued).
What is the fair value of EVMT?
Our model-based fair value for Evome Medical Technologies Inc. is C$0.0063 (as of Jul 5, 2026), built from audited fundamentals. Last price (from Jul 22, 2026): C$0.0050.
What is the quality score of EVMT?
Evome Medical Technologies Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evome Medical Technologies Inc. (EVMT)?
Our model-based price target is the fair value of C$0.0063 (as of Jul 5, 2026) from 1 valuation models. Cautious scenario C$0.0058, optimistic scenario C$0.0073. It is a calculation from audited fundamentals, not an analyst target.
What is the Evome Medical Technologies Inc. stock forecast for 2026?
Our models put fair value at C$0.0063, about +25% upside versus the last price from Jul 22, 2026 of C$0.0050 (undervalued). Cautious scenario C$0.0058, optimistic scenario C$0.0073. The calculation is refreshed regularly with new filings.
What is the revenue of Evome Medical Technologies Inc. (EVMT)?
Evome Medical Technologies Inc. reported trailing-twelve-month revenue of about C$48.3M (latest available figure, as of Jul 5, 2026).
What is the intrinsic value of Evome Medical Technologies Inc. (EVMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evome Medical Technologies Inc. it is C$0.0063 per share (as of Jul 5, 2026), against a price of C$0.0050. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Evome Medical Technologies Inc. stock overvalued or undervalued in 2026?
As of Jul 5, 2026, EVMT trades below its calculated fair value: price C$0.0050, fair value C$0.0063, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVMT?
No. The price is what the market pays today (C$0.0050); the fair value is what the company's own numbers justify (C$0.0063). For Evome Medical Technologies Inc. the two are C$0.0013 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evome Medical Technologies Inc. worth?
The market values Evome Medical Technologies Inc. at about C$399K (market capitalisation, as of Jul 5, 2026). Per share that is C$0.0050; our models calculate a fair value of C$0.0063 per share.
What do the bullish and bearish scenarios say about EVMT?
Our models span a range for Evome Medical Technologies Inc.: cautious scenario C$0.0058, base C$0.0063, optimistic C$0.0073 per share (as of Jul 5, 2026, price C$0.0050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evome Medical Technologies Inc. (EVMT)?
Balance-sheet figures for Evome Medical Technologies Inc. (as of Jul 5, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is EVMT from its 52-week high?
Evome Medical Technologies Inc. trades at C$0.0050, at its 52-week high of C$0.0050 and at the low of C$0.0050 (as of Jul 22, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.0063 is for.
Which stocks are comparable to Evome Medical Technologies Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evome Medical Technologies Inc. stock attractive at the current price?
The data as of Jul 5, 2026: price C$0.0050, calculated fair value C$0.0063 (+25%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVMT calculated?
We run Evome Medical Technologies Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.0063, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Evome Medical Technologies Inc. currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evome Medical Technologies Inc. (EVMT)?
The latest price we hold is from Jul 22, 2026 and stands at C$0.0050. Our model-based fair value is C$0.0063, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evome Medical Technologies Inc. right now?
The price is below even our cautious bear case (C$0.0058). The market is more pessimistic than our downside scenario. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Evome Medical Technologies Inc.
How large is the market capitalisation of Evome Medical Technologies Inc. (EVMT)?
The market capitalisation of Evome Medical Technologies Inc. is C$399K (≈ $280K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Evome Medical Technologies Inc. (EVMT)?
Earnings per share at Evome Medical Technologies Inc. are C$−0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evome Medical Technologies Inc. (EVMT)?
The net margin of Evome Medical Technologies Inc. is −24.9% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evome Medical Technologies Inc. (EVMT)?
The return on equity (ROE) of Evome Medical Technologies Inc. is −295% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evome Medical Technologies Inc. (EVMT)?
On an EBIT basis the return on assets of Evome Medical Technologies Inc. is −17.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evome Medical Technologies Inc. (EVMT)?
The operating margin of Evome Medical Technologies Inc. is −4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evome Medical Technologies Inc. (EVMT)?
Revenue at Evome Medical Technologies Inc. is growing −49.0% versus a year earlier (3y avg +462%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Evome Medical Technologies Inc. (EVMT) generate?
The free cash flow of Evome Medical Technologies Inc. is −C$1.1M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Evome Medical Technologies Inc. in the live analysis
One click puts Evome Medical Technologies Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
